Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy (PROPER)
Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography
Sponsor: Cairo University
Listed as NCT04674254, this PHASE4 trial focuses on Diabetic Retinopathy and Proliferative Diabetic Retinopathy and remains completed. Sponsored by Cairo University, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
May 2021 — Jun 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cairo University
For direct contact, visit the study record on ClinicalTrials.gov .